Agree that PR has merit. It's addressed to both wide industry circles and shareholders. PR sends a message to the industry, collectives, growers, even govt that MG/BB has a new proprietary cryo-extraction process for extraction, stabilization and preservation non-psychoactive mixed cannabinoid carboxylates essential to Dharmanol™.  Of those who know something of the chemistry, it will raise interest and even envy. An achievement on the part of  D. Hoye and Dr. Apel.

The carboxylates (like THCA and CBDA) are found in cannabis juice and are quite unstable after juicing. They are  just starting to be recognized in new studies for significant medicinal value. A recent Harvard study and one in Japan, I believe, found strong anti-tumour effects on breast cancer. Cannabinoid carboxylates have a brief shelf life. And they will readily decarboxylate to pscychoactive form when heated or dried. The technology is another feather in the cap not only for Berkeley Bio but also for SK3 which has another  exclusive license to a new and useful process that gives SKTO a competitive edge.

The PR also shines more light and spreads the word on Dharmanol, our favorite miracle in a diet. The DEMAND is there: "We are happy to have put together more of the elements necessary to fill the large demand anticipated for our Dharmanol™ product line"
-